Live Breaking News & Updates on Evgn

Stay informed with the latest breaking news from Evgn on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Evgn and stay connected to the pulse of your community

Evogene (TSE:EVGN) Price Target Cut to C$4.00 by Analysts at Pi Financial

Evogene (TSE:EVGN – Free Report) had its price objective reduced by Pi Financial from C$5.00 to C$4.00 in a research note released on Wednesday, BayStreet.CA reports. Evogene Price Performance Evogene Company Profile (Get Free Report) Evogene is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including […]

Evogene-company-profile , Free-report , Get-free-report , Computational-predictive-biology , Big-data , Artificial-intelligence , Evogene-daily , Evogene , Tse-evgn , Evgn , Manufacturing

Evogene (NASDAQ:EVGN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN – Free Report) in a report released on Wednesday. The firm issued a sell rating on the biotechnology company’s stock. Evogene Trading Down 5.0 % NASDAQ EVGN opened at $0.63 on Wednesday. The business’s fifty day moving average is $0.79 and its 200 day moving average is […]

Evogene-ltd , Human-health , Nasdaq , Silverarc-capital-management , Securities-exchange-commission , Free-report , Trading-down , Get-free-report , Capital-management , Computational-predictive-biology , Evogene-daily

Silverarc Capital Management LLC Has $1.82 Million Holdings in Evogene Ltd. (NASDAQ:EVGN)

Silverarc Capital Management LLC raised its holdings in Evogene Ltd. (NASDAQ:EVGN – Free Report) by 3,000.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,100,000 shares of the biotechnology company’s stock after purchasing an additional 3,000,000 shares during the quarter. Silverarc Capital […]

United-states , America , Renaissance-technologies , Nasdaq , Evogene-ltd , Silverarc-capital-management , America-corp , Vident-investment-advisory , Exchange-commission , Virtu-financial , Human-health

Evogene Ltd. (NASDAQ:EVGN) Sees Large Decline in Short Interest

Evogene Ltd. (NASDAQ:EVGN – Get Free Report) saw a significant decrease in short interest in December. As of December 15th, there was short interest totalling 187,200 shares, a decrease of 35.0% from the November 30th total of 287,800 shares. Based on an average daily volume of 144,100 shares, the days-to-cover ratio is presently 1.3 days. […]

United-states , America , Vident-investment-advisory , Nasdaq , Silverarc-capital-management , Human-health , America-corp , Renaissance-technologies , Walleye-capital , Alliance-global-partners , Evogene-ltd

Evogene (TSE:EVGN) PT Lowered to C$6.00

Evogene (TSE:EVGN – Free Report) had its price objective cut by Echelon Wealth Partners from C$6.25 to C$6.00 in a report released on Friday morning, BayStreet.CA reports. They currently have a buy rating on the stock. Separately, Desjardins cut their target price on shares of Evogene from C$4.50 to C$4.25 and set a buy rating […]

Evogene-company-profile , Free-report , Echelon-wealth-partners , Get-free-report , Computational-predictive-biology , Big-data , Artificial-intelligence , Evogene-daily , Evogene , Tse-evgn , Evgn

Alliance Global Partners Begins Coverage on Evogene (NASDAQ:EVGN)

Alliance Global Partners assumed coverage on shares of Evogene (NASDAQ:EVGN – Free Report) in a research report released on Monday, Marketbeat reports. The firm issued a buy rating and a $1.85 price objective on the biotechnology company’s stock. A number of other analysts have also recently issued reports on EVGN. StockNews.com began coverage on Evogene […]

Roth-mkm , Evogene-ltd , Nasdaq , Vident-investment-advisory , Alliance-global-partners , Virtu-financial , Silverarc-capital-management , Human-health , Renaissance-technologies , Free-report , Street-capital , Get-free-report

Desjardins Trims Evogene (TSE:EVGN) Target Price to C$4.25

Evogene (TSE:EVGN – Get Free Report) had its target price cut by stock analysts at Desjardins from C$4.50 to C$4.25 in a report issued on Monday, BayStreet.CA reports. The brokerage presently has a “buy” rating on the stock. Evogene Stock Performance About Evogene (Get Free Report) Evogene is a leading computational biology company focused on […]

Get-free-report , Computational-predictive-biology , Big-data , Artificial-intelligence , Evogene-daily , Evogene , Tse-evgn , Evgn , Manufacturing , Lower-price-target , Desjardins

Friday's analyst upgrades and downgrades - The Globe and Mail

Inside the Market’s roundup of some of today’s key analyst actions

Toronto , Ontario , Canada , Vancouver , British-columbia , Shaunavon , Saskatchewan , Swan-hills , Alberta , China , Turner-valley , North-dakota

Lake Street Capital Boosts Evogene (NASDAQ:EVGN) Price Target to $3.00

Evogene (NASDAQ:EVGN – Free Report) had its target price lifted by Lake Street Capital from $2.00 to $3.00 in a research note released on Friday morning, MarketBeat.com reports. They currently have a buy rating on the biotechnology company’s stock. EVGN has been the topic of several other research reports. StockNews.com initiated coverage on Evogene in […]

Roth-mkm , Silverarc-capital-management , Evogene-company-profile , Vident-investment-advisory , Evogene-ltd , Human-health , Renaissance-technologies , Virtu-financial , Free-report , Lake-street-capital , Get-free-report , Investment-advisory

Evogene (NASDAQ:EVGN) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Evogene (NASDAQ:EVGN – Get Free Report) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.02, MarketWatch Earnings reports. Evogene had a negative return on equity of 67.44% and a negative net margin of 943.25%. The firm had […]

United-states , America , Roth-mkm , America-corp , Vident-investment-advisory , Renaissance-technologies , Evogene-ltd , Human-health , Virtu-financial , Get-free-report , Marketwatch-earnings , Investment-advisory